Nucleic acid-drug complex and use thereof

US11613755B2 · kind B2 · utility

Assignee

• Industrial Technology Research Institute · TW

Inventors

• Ping-Fu Cheng · Taichung, TW
• Ya-Ling Chiu · Hsinchu, TW
• Kang Wang · Tangxia, CN
• Po-Yen Lin · Taipei, TW
• Shih-Ta Chen · New Taipei, TW
• Tseng-Huang Liu
• Pei-Shin Jiang · Hsinchu, TW

Key dates

• Filing date: Dec 23, 2020
• Grant date: Mar 28, 2023
• Expiry date: Dec 23, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A nucleic acid-drug complex is provided in the present disclosure, which includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9, in which the CpG oligonucleotide sequence consists of a first fragment and a second fragment, and the nucleic acid sequence of the anti-PD-L1 aptamer is inserted between the first fragment and the second fragment.